Skip to content

Adaptive RadioTherapy for OroPharynx Cancer

Dysphagia | Radiotherapy; Complications | Oropharynx Cancer | MRI | Radiotherapy Side Effect

This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Age ≥18 years
* Ability to provide written informed consent.
* Stage T3-T4N0-3 as per AJCC 8th edition
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
* Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx.
* Planned for curative radiotherapy +/- chemotherapy
* For females of child-bearing age, a negative pregnancy test
* Patients treated with induction chemotherapy can be included if they have residual tumor in place.

Exclusion Criteria:

* Previous irradiation of the head and neck (HNC) region, excluding superficial radiation therapy for non-melanomatous skin cancer
* Previous surgery of the HNC region (except for incisional or excisional biopsies)
* Pregnancy or breastfeeding
* Connective tissue disease
* Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy.
* Patients with contra-indications to MRI will be excluded.

Lieu de l'étude

Centre Hospitalier de l'Université de Montréal
Centre Hospitalier de l'Université de Montréal
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Mom Phat

[email protected]
514-890-8254
Backup Contact

Silvine Benth

[email protected]
514-890-8254
Étude parrainée par
Centre hospitalier de l'Université de Montréal (CHUM)
Participants recherchés
Plus d'informations
ID de l'étude: NCT04901234